Joshua Richter, MD, Icahn School of Medicine at Mount Sinai, New York, NY Recorded on September 10, 2021 Treating myeloma patients, especially newly diagnosed, can be very complex. How are treatment decisions determined? Who is eligible to receive a transplant? What is the patient’s role in making treatment decisions? In this month’s episode, Dr. Joshua Richter from the Icahn School of Medicine at Mount Sinai Hospital in New York, provides his perspective on treating newly diagnosed myeloma patients, including smoldering myeloma, describes the evolution of CRAB criteria to SLIM CRAB criteria, discusses the importance of quality-of-life considerations, describes how COVID-19 has affected treatment, and reviews exciting myeloma treatment options on the horizon.   Joshua Richter, MD Assistant Professor of Medicine Tisch Cancer Institute Icahn School of Medicine at Mount Sinai Director of Myeloma Blavatnik Family Chelsea Medical Center at Mount Sinai New York, NY This podcast episode is supported by Janssen Oncology, Pharmaceutical Companies of Johnson & Johnson.